Johnson & Johnson Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Johnson & Johnson ha aumentado sus beneficios a una tasa media anual de 6.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 9.7% anual. Los ingresos han ido creciendo a una tasa media de 1.6% al año. La rentabilidad financiera de Johnson & Johnson es de 25.9%, y sus márgenes netos son de 21.8%.
Información clave
6.82%
Tasa de crecimiento de los beneficios
9.54%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 5.95% |
| Tasa de crecimiento de los ingresos | 1.65% |
| Rentabilidad financiera | 25.92% |
| Margen neto | 21.83% |
| Última actualización de beneficios | 29 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Seeking Alpha • May 23
Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
Summary Johnson & Johnson is rated Hold, trading near intrinsic value with limited upside based on a 20x multiple and $12 normalized EPS. Q1 results showed 10% sales growth and a $450M revenue beat, with management raising FY 2026 guidance and extending the dividend growth streak to 64 years. JNJ faces headwinds from biosimilar and generic competition, MedTech challenges, and commercial sluggishness, but maintains strong FCF yield and a robust product pipeline. Technicals are mixed but lean bullish, with $235 as near-term resistance and investors advised to monitor upcoming conference commentary and sector momentum. Read the full article on Seeking Alpha
Actualización de narrativa • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Actualización de narrativa • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Actualización de narrativa • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
Nueva narrativa • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.Actualización de narrativa • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Nueva narrativa • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Actualización de narrativa • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Actualización de narrativa • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Actualización de narrativa • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Nueva narrativa • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Actualización de narrativa • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.Actualización de narrativa • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.Actualización de narrativa • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.Actualización de narrativa • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.Actualización de narrativa • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Johnson & Johnson. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 29 Mar 26 | 96,362 | 21,040 | 24,003 | 14,967 |
| 28 Dec 25 | 94,193 | 26,804 | 23,130 | 14,665 |
| 28 Sep 25 | 92,149 | 25,119 | 22,742 | 15,711 |
| 29 Jun 25 | 90,627 | 22,661 | 22,211 | 16,991 |
| 30 Mar 25 | 89,331 | 21,810 | 21,906 | 16,915 |
| 29 Dec 24 | 88,821 | 14,066 | 21,952 | 17,232 |
| 29 Sep 24 | 87,696 | 14,767 | 21,290 | 16,414 |
| 30 Jun 24 | 86,576 | 16,382 | 21,050 | 14,909 |
| 31 Mar 24 | 85,648 | 17,072 | 20,640 | 15,172 |
| 31 Dec 23 | 85,159 | 13,326 | 20,166 | 15,085 |
| 01 Oct 23 | 83,703 | 12,421 | 19,648 | 14,315 |
| 02 Jul 23 | 82,348 | 12,422 | 19,323 | 14,353 |
| 02 Apr 23 | 77,458 | 10,730 | 17,993 | 14,128 |
| 01 Jan 23 | 79,990 | 16,370 | 19,078 | 14,135 |
| 02 Oct 22 | 84,855 | 17,879 | 21,037 | 15,145 |
| 03 Jul 22 | 88,197 | 17,236 | 22,197 | 15,082 |
| 03 Apr 22 | 94,880 | 19,830 | 24,430 | 14,998 |
| 02 Jan 22 | 78,740 | 17,801 | 19,506 | 14,277 |
| 03 Oct 21 | 91,446 | 17,880 | 23,364 | 14,026 |
| 04 Jul 21 | 89,190 | 17,767 | 22,852 | 13,444 |
| 04 Apr 21 | 84,214 | 15,115 | 21,817 | 12,757 |
| 03 Jan 21 | 82,584 | 14,714 | 21,731 | 12,159 |
| 27 Sep 20 | 80,856 | 16,986 | 21,681 | 11,359 |
| 28 Jun 20 | 80,503 | 15,185 | 21,625 | 11,118 |
| 29 Mar 20 | 82,729 | 17,166 | 22,185 | 11,077 |
| 29 Dec 19 | 82,059 | 15,119 | 21,885 | 11,355 |
| 29 Sep 19 | 81,706 | 14,151 | 21,957 | 11,347 |
| 30 Jun 19 | 81,325 | 16,332 | 22,191 | 11,256 |
| 31 Mar 19 | 81,593 | 14,679 | 22,437 | 11,229 |
| 30 Dec 18 | 81,581 | 15,297 | 22,540 | 10,775 |
| 30 Sep 18 | 81,382 | 1,542 | 22,454 | 11,194 |
| 01 Jul 18 | 80,684 | 1,372 | 22,300 | 11,271 |
| 01 Apr 18 | 78,693 | 1,245 | 21,758 | 10,928 |
| 31 Dec 17 | 76,450 | 1,300 | 21,520 | 10,594 |
| 01 Oct 17 | 74,361 | 15,827 | 20,600 | 9,591 |
| 02 Jul 17 | 72,531 | 16,335 | 20,012 | 9,184 |
| 02 Apr 17 | 72,174 | 16,505 | 20,020 | 9,152 |
| 01 Jan 17 | 71,890 | 16,540 | 19,793 | 9,143 |
| 02 Oct 16 | 71,595 | 15,941 | 20,527 | 9,319 |
| 03 Jul 16 | 70,877 | 15,027 | 20,836 | 9,295 |
| 03 Apr 16 | 70,182 | 15,546 | 21,044 | 9,160 |
| 03 Jan 16 | 70,074 | 15,409 | 21,203 | 9,046 |
| 27 Sep 15 | 70,517 | 14,715 | 21,134 | 8,817 |
| 28 Jun 15 | 71,882 | 16,106 | 21,521 | 8,686 |
Ingresos de calidad: JNJ tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(21.8%) de JNJ son inferiores a los del año pasado (24.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de JNJ han crecido un 6.8% al año en los últimos 5 años.
Acelerando crecimiento: JNJ ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: JNJ tuvo un crecimiento negativo de los beneficios (-3.2%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-5%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (25.9%) de JNJ se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 01:21 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/29 |
| Ingresos anuales | 2025/12/28 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Johnson & Johnson está cubierta por 53 analistas. 23 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |